BioSpace News Archive

VYNE Therapeutics Inc. today announced that David Domzalski, Chief Executive Officer, will participate in a virtual fireside chat at the 42nd Annual Cowen Healthcare Conference on March 8, 2022.

Cocrystal Pharma, Inc. announces that management will participate in two upcoming investment conferences as follows.

Pharvaris announced that management will participate in three upcoming investor conferences in March.

Athena Bioscience, LLC announced plans for the commercial launch of Nexiclon XR, the only once-daily clonidine extended-release tablets indicated for treatment of hypertension.

NephroSant™ announced that the Journal of Clinical Medicine has published real-world data (RWD) that provides insight into how changes in allograft health are reflected in specific ranges of QSant™ scores.

Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference.

Pandemic Response Lab (PRL), a wholly-owned subsidiary of Opentrons Labworks, Inc., today announced the launch in its Rockville, Maryland lab of its concise respiratory panel, which simultaneously tests four viruses: SARS-CoV-2, influenza A and B, and respiratory syncytial virus (RSV).

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that a new, wholly owned subsidiary of Lucid, LucidDx Labs Inc. (“LucidDx Labs”) has acquired from ResearchDx, Inc.

Mereo BioPharma Group plc today announced it will host a virtual R&D Day on Monday, March 14, 2022, to review the Company’s alvelestat (MPH966) program.

MediWound Ltd., a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, announced the pricing of an underwritten public offering of 5,208,333 ordinary shares at a public offering price of $1.92 per share.